Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Terminated · Phase 2 · NCT06118099
Conditions: Hidradenitis
At a glance
- Research payments reported, 2025
- $169,322
- U.S. investigators named
- 10
- Sites paid
- 11
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- Sanofi
- Tested
- Amlitelimab (drug), Placebo (drug)
- Dates
- Started 2023-11-01; completion 2025-10-10
- Results posted
- Not yet
This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to measure standardized clinician reported and participant-reported outcomes (ClinRO and PRO), safety, and drug concentration. An optional long-term extension (LTE) period will assess chronic safety and efficacy over an additional 80 weeks of amlitelimab treatment. Study details include: * The…
From ClinicalTrials.gov, last updated 2026-02-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $169,322 in research payments for this study in 2025 (66 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lindsay S. Ackerman, MD Dermatology · Phoenix, AZ
- Sunil S. Dhawan, MD Dermatology · Fremont, CA
- Ann Lin, DO Dermatology · Tampa, FL
- Milan J. Anadkat, MD Dermatology · Saint Louis, MO
- Kaharu Sumino, MD Pulmonology · Saint Louis, MO
- Kevin Donnelly, M. D. Dermatology · Westerville, OH
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Ronald T. Plott, M.D. Dermatology · Fort Worth, TX
- Tanya R. Rodgers, MD Dermatology · Allen, TX
- Stephen K. Tyring, MD PHD Dermatology · Webster, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of South Florida $28,266
- Center for Clinical Studies Ltd LLP $26,802
- Stryde Consulting Llc $25,922
- Washington University $23,527
- Vast Clinical Research Llc $17,671
- Cr Services Acquisition Us Llc $13,808
- Aventiv Research Columbus $12,473
- Oliver Street Dermatology Managemen U S Dermatology PArtners Southwest Skin Specialists Llc $11,316
- Center for Dermatology Clinical Research Inc $6,900
- Cr Services Acquisition Us Llc Centricity Research $2,278
- Clinical PArtners Llc $360
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.